PHILADELPHIA--(BUSINESS WIRE)--Accelerated Biosciences and Stemmatters are thrilled to announce their strategic partnership aimed at co-developing and co-marketing human induced pluripotent stem cells ...

HAMBURG, GERMANY / ACCESSWIRE / December 19, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has received a US$ 2.5 m ...

Fate Therapeutics' off-the-shelf cell therapy product platform, including FT819, is gaining significant exposure by being selected for an oral presentation at the prominent EULAR 2025 congress. The ...

SAN DIEGO--(BUSINESS WIRE)--Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of off-the-shelf neuron ...

PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (IPSC) (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies ...

PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in ...

This data represents a step forward in developing next-generation ‘off-the-shelf’ iPSC derived gamma-delta T cells. Our proprietary expansion methods are serum and feeder-free and have the potential ...

This data represents a step forward in developing next-generation ‘off-the-shelf’ iPSC derived gamma-delta T cells. Our proprietary expansion methods are serum and feeder-free and have the potential ...

Induced pluripotent stem cell technology is a promising, rapidly evolving field with the potential to transform cell-based therapeutics across a range of disease areas that have significant unmet ...

iXCells’ cell engineering platform iPSCore ™ is a unified and dedicated system where tools, skills, experiences and expertise are structured together to design, develop and build iPSC-derived cell ...

In vitro data showcases CNTY-101’s ability to induce CD19-specific cytolysis of B-cells and potential to treat B-cell driven autoimmune diseases including systemic lupus erythematosus (SLE) ...